{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:12:09Z","timestamp":1794532329293,"version":"4.9.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Melanoma is a highly aggressive skin cancer with biologically distinct subtypes. Acral melanoma (AM), a rare but particularly aggressive form, often presents with lymph node (LN) metastasis at diagnosis. Despite its clinical severity, the mechanisms underlying its metastatic behavior remain unclear. Emerging studies suggest the tumor microenvironment as a key driver of metastatic niche formation, but its specific role in AM progression is not well characterized. To investigate the role of the tumor microenvironment in AM progression, we performed single-cell RNA sequencing (scRNA-seq) on tumor tissues and matched adjacent normal samples from treatment-na\u00efve AM patients, comparing cases with (LN\n                    <jats:sup>+<\/jats:sup>\n                    ) and without (LN\n                    <jats:sup>-<\/jats:sup>\n                    ) lymph node metastasis. Key transcriptomic findings were validated by immunofluorescence staining. Functional relevance was tested by conducting in vitro and in vivo assays. An independent validation cohort was employed to confirm key observations and evaluate prognostic associations. Our results reveal preferential SPP1\n                    <jats:sup>+<\/jats:sup>\n                    signaling pathways, including autocrine amplification within secreted phosphoprotein (SPP) 1\n                    <jats:sup>+<\/jats:sup>\n                    macrophages and their interactions with S100A8\n                    <jats:sup>+<\/jats:sup>\n                    melanoma cells via the SPP1-CD44 axis. S100A8\n                    <jats:sup>+<\/jats:sup>\n                    melanoma cells emerged as the predominant malignant subpopulation in LN metastatic tumors (56.3% versus 34.7% in non-metastatic cases). Clinically, elevated SPP1 expression emerged as an independent predictor of poor overall survival. In vivo, anti-SPP1 therapy induced a macrophage phenotype switch and significantly reduced tumor burden. Together, these findings indicate that LN\n                    <jats:sup>+<\/jats:sup>\n                    AM is characterized by an SPP1\n                    <jats:sup>+<\/jats:sup>\n                    macrophage-driven immunosuppressive microenvironment and highlight the SPP1-CD44 axis as a promising therapeutic target for limiting AM dissemination.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08755-5","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:56:01Z","timestamp":1776830161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SPP1+ macrophage-driven interactions shape the tumor microenvironment in lymph node metastatic acral melanoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Yao","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimou","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangrui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoqia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8124-7491","authenticated-orcid":false,"given":"Xiaolong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-9354","authenticated-orcid":false,"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"8755_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semcancer.2019.10.017","volume":"61","author":"YA Chen","year":"2020","unstructured":"Chen YA, Teer JK, Eroglu Z, Wu JY, Koomen JM, Karreth FA, et al. Translational pathology, genomics and the development of systemic therapies for acral melanoma. Semin Cancer Biol. 2020;61:149\u201357.","journal-title":"Semin Cancer Biol"},{"key":"8755_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03532-2","volume":"20","author":"J Gui","year":"2022","unstructured":"Gui J, Guo Z, Wu D. Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma. J Transl Med. 2022;20:367.","journal-title":"J Transl Med"},{"key":"8755_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380.","journal-title":"Nature"},{"key":"8755_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell F, Wilmott JS, Johansson PA, Nones K, Addala V, Mukhopadhyay P, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020;11:5259.","journal-title":"Nat Commun"},{"key":"8755_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34877-3","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang C, Shen H, Yang T, Li T, Liu X, Wang J, et al. A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nat Commun. 2022;13:7250.","journal-title":"Nat Commun"},{"key":"8755_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"8755_CR7","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","volume":"28","author":"J Li","year":"2022","unstructured":"Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, et al. Single-cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy. Clin Cancer Res. 2022;28:2131\u201346.","journal-title":"Clin Cancer Res"},{"key":"8755_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","volume":"176","author":"Y Nakamura","year":"2022","unstructured":"Nakamura Y, Namikawa K, Kiniwa Y, Kato H, Yamasaki O, Yoshikawa S, et al. Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: a retrospective, multicenter study of 254 Japanese patients. Eur J Cancer. 2022;176:78\u201387.","journal-title":"Eur J Cancer"},{"key":"8755_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43980-y","volume":"14","author":"C Wei","year":"2023","unstructured":"Wei C, Sun W, Shen K, Zhong J, Liu W, Gao Z, et al. Delineating the early dissemination mechanisms of acral melanoma by integrating single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:8119.","journal-title":"Nat Commun"},{"key":"8755_CR10","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1200\/JCO.19.03034","volume":"38","author":"C Garbe","year":"2020","unstructured":"Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, et al. Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III Melanoma cohorts. J Clin Oncol. 2020;38:2543\u201351.","journal-title":"J Clin Oncol"},{"key":"8755_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.019","volume":"185","author":"NE Reticker-Flynn","year":"2022","unstructured":"Reticker-Flynn NE, Zhang W, Belk JA, Basto PA, Escalante NK, Pilarowski GOW, et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell. 2022;185:1924\u201342.e23.","journal-title":"Cell"},{"key":"8755_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1021057","volume":"12","author":"KE Rhodin","year":"2022","unstructured":"Rhodin KE, Fimbres DP, Burner DN, Hollander S, O\u2019Connor MH, Beasley GM. Melanoma lymph node metastases - moving beyond quantity in clinical trial design and contemporary practice. Front Oncol. 2022;12:1021057.","journal-title":"Front Oncol"},{"key":"8755_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-023-01576-4","volume":"8","author":"H Ji","year":"2023","unstructured":"Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S, et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduct Target Ther. 2023;8:367.","journal-title":"Signal Transduct Target Ther"},{"key":"8755_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"8755_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28566-4","volume":"13","author":"F Farshidfar","year":"2022","unstructured":"Farshidfar F, Rhrissorrakrai K, Levovitz C, Peng C, Knight J, Bacchiocchi A, et al. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun. 2022;13:898.","journal-title":"Nat Commun"},{"key":"8755_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217618","volume":"617","author":"C Liu","year":"2025","unstructured":"Liu C, Xia S, Wang B, Li J, Wang X, Ren Y, et al. Osteopontin promotes tumor microenvironment remodeling and therapy resistance. Cancer Lett. 2025;617:217618.","journal-title":"Cancer Lett"},{"key":"8755_CR17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12672-025-04273-6","volume":"17","author":"Y Feng","year":"2025","unstructured":"Feng Y, Shao X, Xu ZF, Liu P, Wu H, Cheng Y, et al. SPP1 regulates tumor progression through modulation of signaling pathways and the tumor microenvironment. Discov Oncol. 2025;17:115.","journal-title":"Discov Oncol"},{"key":"8755_CR18","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1158\/0008-5472.CAN-25-1486","volume":"85","author":"Y Gu","year":"2025","unstructured":"Gu Y, Muller WJ. The multifaceted role of osteopontin in modulating the tumor microenvironment. Cancer Res. 2025;85:4049\u201361.","journal-title":"Cancer Res"},{"key":"8755_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1711015","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Wang Y, Liu Y, Yang R. SPP1(+) macrophages in tumor immunosuppression: mechanisms and therapeutic implications. Front Immunol. 2025;16:1711015.","journal-title":"Front Immunol"},{"key":"8755_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13046-024-03151-3","volume":"43","author":"L Levati","year":"2024","unstructured":"Levati L, Tabolacci C, Facchiano A, Facchiano F, Alvino E, Antonini Cappellini GC, et al. Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy. J Exp Clin Cancer Res. 2024;43:226.","journal-title":"J Exp Clin Cancer Res"},{"key":"8755_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1756-9966-31-83","volume":"31","author":"R Ozasa","year":"2012","unstructured":"Ozasa R, Ohno J, Iwahashi T, Taniguchi K. Tumor-induced lymphangiogenesis in cervical lymph nodes in oral melanoma-bearing mice. J Exp Clin Cancer Res. 2012;31:83.","journal-title":"J Exp Clin Cancer Res"},{"key":"8755_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41576-023-00586-w","volume":"24","author":"L Heumos","year":"2023","unstructured":"Heumos L, Schaar AC, Lance C, Litinetskaya A, Drost F, Zappia L, et al. Best practices for single-cell analysis across modalities. Nat Rev Genet. 2023;24:550\u201372.","journal-title":"Nat Rev Genet"},{"key":"8755_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.12688\/f1000research.73600.1","volume":"10","author":"PL Germain","year":"2021","unstructured":"Germain PL, Lun A, Garcia MeixideC, Macnair W, Robinson MD. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res. 2021;10:979.","journal-title":"F1000Res"},{"key":"8755_CR24","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387.e29.","journal-title":"Cell"},{"key":"8755_CR25","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41592-018-0229-2","volume":"15","author":"R Lopez","year":"2018","unstructured":"Lopez R, Regier J, Cole MB, Jordan MI, Yosef N. Deep generative modeling for single-cell transcriptomics. Nat Methods. 2018;15:1053\u20138.","journal-title":"Nat Methods"},{"key":"8755_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science"},{"key":"8755_CR27","unstructured":"Tickle T, Gc Ti, Brown, M. & Haas, B. InferCNV of the Trinity CTAT Project. 2019.Available from: https:\/\/github.com\/broadinstitute\/inferCNV."},{"key":"8755_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"8755_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2020;17:159\u201362.","journal-title":"Nat Methods"},{"key":"8755_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ccell.2024.04.012","volume":"42","author":"H Liu","year":"2024","unstructured":"Liu H, Gao J, Feng M, Cheng J, Tang Y, Cao Q, et al. Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. Cancer Cell. 2024;42:1067\u201385.e11.","journal-title":"Cancer Cell"},{"key":"8755_CR31","doi-asserted-by":"crossref","unstructured":"Panda VK, Mishra B, Nath AN, Butti R, Yadav AS, Malhotra D, et al. Osteopontin: a key multifaceted regulator in tumor progression and immunomodulation. Biomedicines. 2024;12.","DOI":"10.20944\/preprints202405.0835.v1"},{"key":"8755_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.956225","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Ni C, Lu H. Polo-Like Kinase 2: from principle to practice. Front Oncol. 2022;12:956225.","journal-title":"Front Oncol"},{"key":"8755_CR33","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1161\/ATVBAHA.113.300168","volume":"33","author":"A Mantovani","year":"2013","unstructured":"Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol. 2013;33:1478\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"8755_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39\u201351.","journal-title":"Cell"},{"key":"8755_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361.","journal-title":"Immunity"},{"key":"8755_CR36","doi-asserted-by":"crossref","unstructured":"Varanasi SM, Gulani Y, Rachamala HK, Mukhopadhyay D, Angom RS. Neuropilin-1: a multifaceted target for cancer therapy. Curr Oncol. 2025;32.","DOI":"10.3390\/curroncol32040203"},{"key":"8755_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13046-024-02991-3","volume":"43","author":"K Li","year":"2024","unstructured":"Li K, Xue W, Lu Z, Wang S, Zheng J, Lu K, et al. Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer. J Exp Clin Cancer Res. 2024;43:59.","journal-title":"J Exp Clin Cancer Res"},{"key":"8755_CR38","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2025.03.035","volume":"83","author":"T Cui","year":"2025","unstructured":"Cui T, Sun L, Guo X, Cheng C, Zhang N, Zhou S, et al. Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response. J Hepatol. 2025;83:946\u201358.","journal-title":"J Hepatol"},{"key":"8755_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41422-022-00769-w","volume":"33","author":"OE Villarreal","year":"2023","unstructured":"Villarreal OE, Kopetz S. EMP1(+) tumor cells drive metastatic relapse. Cell Res. 2023;33:337\u20138.","journal-title":"Cell Res"},{"key":"8755_CR40","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ccell.2019.04.003","volume":"35","author":"M Segovia","year":"2019","unstructured":"Segovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, et al. Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation. Cancer Cell. 2019;35:767\u201381.e6.","journal-title":"Cancer Cell"},{"key":"8755_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.859958","volume":"10","author":"L Jiang","year":"2022","unstructured":"Jiang L, Yang Y, Liu F, Ma M, Gao J, Sun L, et al. A potential diagnostic and prognostic biomarker TMEM176B and its relationship with immune infiltration in skin cutaneous melanoma. Front Cell Dev Biol. 2022;10:859958.","journal-title":"Front Cell Dev Biol"},{"key":"8755_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27906","volume":"10","author":"J Xie","year":"2024","unstructured":"Xie J, Zhu L, Yang X, Yu F, Fan B, Wu Y, et al. Combination of theoretical analysis and experiments: Exploring the role of PLA2G7 in human cancers, including renal cancer. Heliyon. 2024;10:e27906.","journal-title":"Heliyon"},{"key":"8755_CR43","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/0008-5472.CAN-24-0253","volume":"84","author":"JR Feng","year":"2024","unstructured":"Feng JR, Li X, Han C, Chang Y, Fu Y, Feng GC, et al. C-reactive protein induces immunosuppression by activating FcgammaR2B in pulmonary macrophages to promote lung metastasis. Cancer Res. 2024;84:4184\u201398.","journal-title":"Cancer Res"},{"key":"8755_CR44","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s12276-024-01163-9","volume":"56","author":"SG Lee","year":"2024","unstructured":"Lee SG, Woo SM, Seo SU, Lee CH, Baek MC, Jang SH, et al. Cathepsin D promotes polarization of tumor-associated macrophages and metastasis through TGFBI-CCL20 signaling. Exp Mol Med. 2024;56:383\u201394.","journal-title":"Exp Mol Med"},{"key":"8755_CR45","doi-asserted-by":"publisher","first-page":"e0286056","DOI":"10.1371\/journal.pone.0286056","volume":"18","author":"T Liu","year":"2023","unstructured":"Liu T, Huang T, Li J, Li A, Li C, Huang X, et al. Optimization of differentiation and transcriptomic profile of THP-1 cells into macrophage by PMA. PLoS One. 2023;18:e0286056.","journal-title":"PLoS One"},{"key":"8755_CR46","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.7150\/thno.42385","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Meng J, Deng S, Zhang L, Wan C, Lu L, et al. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. Theranostics. 2020;10:3049\u201363.","journal-title":"Theranostics"},{"key":"8755_CR47","doi-asserted-by":"publisher","first-page":"26991","DOI":"10.1074\/jbc.M311838200","volume":"279","author":"LY Bourguignon","year":"2004","unstructured":"Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E. CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem. 2004;279:26991\u20137007.","journal-title":"J Biol Chem"},{"key":"8755_CR48","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2008.03.007","volume":"18","author":"LY Bourguignon","year":"2008","unstructured":"Bourguignon LY. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol. 2008;18:251\u20139.","journal-title":"Semin Cancer Biol"},{"key":"8755_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1083\/jcb.150.1.177","volume":"150","author":"LY Bourguignon","year":"2000","unstructured":"Bourguignon LY, Zhu H, Shao L, Chen YW. Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J Cell Biol. 2000;150:177\u201391.","journal-title":"J Cell Biol"},{"key":"8755_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamadermatol.2021.4812","volume":"158","author":"S Cheraghlou","year":"2022","unstructured":"Cheraghlou S, Ugwu N, Girardi M. Sentinel lymph node biopsy positivity in patients with acral lentiginous and other subtypes of cutaneous melanoma. JAMA Dermatol. 2022;158:51\u20138.","journal-title":"JAMA Dermatol"},{"key":"8755_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21055","volume":"9","author":"Z Yan","year":"2023","unstructured":"Yan Z, Hu X, Tang B, Deng F. Role of osteopontin in cancer development and treatment. Heliyon. 2023;9:e21055.","journal-title":"Heliyon"},{"key":"8755_CR52","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.2147\/JIR.S505237","volume":"18","author":"K Wang","year":"2025","unstructured":"Wang K, Wan J, Zheng R, Xiao Y, Lv F, Ge H, et al. SPP1 as a prognostic and immunotherapeutic biomarker in gliomas and other cancer types: a pan-cancer study. J Inflamm Res. 2025;18:2247\u201365.","journal-title":"J Inflamm Res"},{"key":"8755_CR53","doi-asserted-by":"crossref","unstructured":"Palma A. The landscape of SPP1(+) Macrophages across tissues and diseases: a comprehensive review. Immunology. 2025.","DOI":"10.1111\/imm.13952"},{"key":"8755_CR54","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor-infiltrating myeloid cells. Cell. 2021;184:792\u2013809.e23.","journal-title":"Cell"},{"key":"8755_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.749210","volume":"9","author":"J Wei","year":"2021","unstructured":"Wei J, Chen Z, Hu M, He Z, Jiang D, Long J, et al. Characterizing intercellular communication of pan-cancer reveals SPP1+ tumor-associated macrophage expanded in hypoxia and promoting cancer malignancy through single-cell RNA-Seq Data. Front Cell Dev Biol. 2021;9:749210.","journal-title":"Front Cell Dev Biol"},{"key":"8755_CR56","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.7150\/thno.109097","volume":"15","author":"Q Ge","year":"2025","unstructured":"Ge Q, Meng J, Wang Z, Anwaier A, Lu J, Tian X, et al. Spatially segregated APOE(+) macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma. Theranostics. 2025;15:5312\u201336.","journal-title":"Theranostics"},{"key":"8755_CR57","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R, Wirapati P, Messemaker M, Roh W, Zitti B, Duval F, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381:515\u201324.","journal-title":"Science"},{"key":"8755_CR58","doi-asserted-by":"crossref","unstructured":"Fan H, Li X, Zhao Y, Song L, Sun L, Wu Z, et al. Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies. J Neurooncol. 2025.","DOI":"10.1007\/s11060-025-05116-8"},{"key":"8755_CR59","doi-asserted-by":"crossref","unstructured":"Seo ES, Park S, Cho EY, Lee JE, Jung HH, Hyeon J, et al. Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype. Cell Rep Med. 2025;6.","DOI":"10.1016\/j.xcrm.2025.102164"},{"key":"8755_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00967-w","volume":"9","author":"L Qiu","year":"2025","unstructured":"Qiu L, Zhao X, Yao S, Fei Y, Gong Y, Zhou Z, et al. Multi-omics analyses reveal interactions between GREM1+ fibroblasts and SPP1+ macrophages in gastric cancer. NPJ Precis Oncol. 2025;9:164.","journal-title":"NPJ Precis Oncol"},{"key":"8755_CR61","doi-asserted-by":"crossref","unstructured":"Trehan R, Huang P, Zhu XB, Wang X, Soliman M, Strepay D, et al. SPP1+ macrophages cause exhaustion of tumor-specific T cells in liver metastases. Nat Commun. 2025;16.","DOI":"10.1038\/s41467-025-59529-0"},{"key":"8755_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06565-5","volume":"23","author":"P Zhou","year":"2025","unstructured":"Zhou P, Tang T, Zhao P, Wang Q, Hu X, Si J, et al. Unveiling the hidden dance: SPP1 + macrophages identified in ulcerative colitis reveal crosstalk with CHI3L1 + fibroblasts. J Transl Med. 2025;23:567.","journal-title":"J Transl Med"},{"key":"8755_CR63","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O\u2019Brien SA, et al. Single-CELL ANALYSES INFORM MECHANISMS OF MYELOID-TARGETED THERAPIES IN COLON CANcer. Cell. 2020;181:442\u201359.e29.","journal-title":"Cell"},{"key":"8755_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40164-024-00571-x","volume":"13","author":"SZ Xie","year":"2024","unstructured":"Xie SZ, Yang LY, Wei R, Shen XT, Pan JJ, Yu SZ, et al. Targeting SPP1-orchestrated neutrophil extracellular traps-dominant pre-metastatic niche reduced HCC lung metastasis. Exp Hematol Oncol. 2024;13:111.","journal-title":"Exp Hematol Oncol"},{"key":"8755_CR65","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1007\/s00262-023-03493-5","volume":"72","author":"L Modestino","year":"2023","unstructured":"Modestino L, Cristinziano L, Trocchia M, Ventrici A, Capone M, Madonna G, et al. Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps. Cancer Immunol Immunother. 2023;72:3363\u201376.","journal-title":"Cancer Immunol Immunother"},{"key":"8755_CR66","doi-asserted-by":"crossref","unstructured":"Liu X, Ren Z, Tan C, Nunez-Santana FL, Kelly ME, Yan Y, et al. Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis. J Clin Invest. 2024;134","DOI":"10.1172\/JCI179527"},{"key":"8755_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116840","volume":"235","author":"J Chen","year":"2025","unstructured":"Chen J, Xu M, Wu F, Wu N, Li J, Xie Y, et al. CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K\/AKT and NLRP3\/GSDMD pathways. Biochem Pharmacol. 2025;235:116840.","journal-title":"Biochem Pharmacol"},{"key":"8755_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13046-025-03303-z","volume":"44","author":"Z Pan","year":"2025","unstructured":"Pan Z, Chen J, Xu T, Cai A, Han B, Li Y, et al. VSIG4(+) tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1. J Exp Clin Cancer Res. 2025;44:45.","journal-title":"J Exp Clin Cancer Res"},{"key":"8755_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06018-5","volume":"22","author":"J Zhang","year":"2024","unstructured":"Zhang J, Peng Q, Fan J, Liu F, Chen H, Bi X, et al. Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC. J Transl Med. 2024;22:1157.","journal-title":"J Transl Med"},{"key":"8755_CR70","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637:1207\u201317.","journal-title":"Nature"},{"key":"8755_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1323933","volume":"14","author":"MM Dugan","year":"2024","unstructured":"Dugan MM, Perez MC, Karapetyan L, Zager JS. Management of acral lentiginous melanoma: current updates and future directions. Front Oncol. 2024;14:1323933.","journal-title":"Front Oncol"},{"key":"8755_CR72","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/ijc.35060","volume":"155","author":"M Bloem","year":"2024","unstructured":"Bloem M, van Not OJ, Aarts MJB, van den Berkmortel F, Blank CU, Blokx WAM, et al. Adjuvant treatment with anti-PD-1 in acral melanoma: a nationwide study. Int J Cancer. 2024;155:1455\u201365.","journal-title":"Int J Cancer"},{"key":"8755_CR73","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/bjd\/ljae401","volume":"192","author":"E McGillivray","year":"2025","unstructured":"McGillivray E, Ashouri K, Chatziioannou E, Gallegos JAO, Zarka J, Kechter J, et al. Combined programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma. Br J Dermatol. 2025;192:316\u201326.","journal-title":"Br J Dermatol"},{"key":"8755_CR74","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/stmcls\/sxae060","volume":"42","author":"SJ Sonnentag","year":"2024","unstructured":"Sonnentag SJ, Ibrahim NSM, Orian-Rousseau V. CD44: a stemness driver, regulator, and marker-all in one? Stem Cells. 2024;42:1031\u20139.","journal-title":"Stem Cells"},{"key":"8755_CR75","doi-asserted-by":"publisher","DOI":"10.31083\/FBL24821","volume":"30","author":"JM Gama","year":"2025","unstructured":"Gama JM, Oliveira RC. CD44 and its role in solid cancers - a review: from tumor progression to prognosis and targeted therapy. Front Biosci (Landmark Ed). 2025;30:24821.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"8755_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102224","volume":"52","author":"YF Melzer","year":"2025","unstructured":"Melzer YF, Fergen NL, Mess C, Stadler JC, Geidel G, Schwietzer YA, et al. Evaluation of S100A8\/A9 and neutrophils as prognostic markers in metastatic melanoma patients under immune-checkpoint inhibition. Transl Oncol. 2025;52:102224.","journal-title":"Transl Oncol"},{"key":"8755_CR77","doi-asserted-by":"crossref","unstructured":"Ozbay Kurt FG, Cicortas BA, Balzasch BM, De la Torre C, Ast V, Tavukcuoglu E, et al. S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling. J Immunother Cancer. 2024;12.","DOI":"10.1136\/jitc-2024-009552"},{"key":"8755_CR78","doi-asserted-by":"crossref","unstructured":"Tomonobu N, Kinoshita R, Wake H, Inoue Y, Ruma IMW, Suzawa K, et al. Histidine-rich glycoprotein suppresses the S100a8\/a9-mediated organotropic metastasis of melanoma cells. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms231810300"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08755-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08755-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:15:41Z","timestamp":1780463741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08755-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8755"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08755-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All participants provided written informed consent in accordance with protocols approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (Approval No. IRB2022-337-01). All mice were adults. All procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (protocol SYSU-IACUC-2024-002157) and conducted in accordance with the National Research Council\u2019s Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"531"}}